The two isomers 3'-azido-3'-deoxythymidine 5'-triphosphate (erythro-AZT-TP) and 1-(3'-azido-2',3'-dideoxy-(-D-xylofuranosyl)thymine 5'-triphosphate (threo-AZT-TP) were studied as inhibitors of the reverse transcriptase activity of avian myelobastosis virus. Kinetic analysis of the (rA)n (dT)12.18 (a standard template primer complex of polyriboadenylate and oligodeoxythymidylate of indicated length)-directed reaction revealed that erythro-AZT-TP was a competitive inhibitor with respect to dTTP, whereas threo-AZT-TP was a noncompetitive inhibitor. The apparent Ki values, as calculated from Dixon plots, were 0.48 and 5.5 ,uM, respectively, compared with a Km value for dTTP of about 70 ,iM. These results indicate that erythro-AZT-TP had an approximately 150-times-higher affinity to the enzyme than dTTP had and that the avian myeloblastosis virus reverse transcriptase had different binding sites for the two isomers.
Reverse transcriptases are virus-coded enzymes which are obligatory and specific for the multiplication of retroviruses and therefore possible targets for antiviral chemotherapy. Several compounds inhibit the reverse transcriptase activity of various retroviruses (1-3, 9, 12 ). An effective inhibitor of reverse transcriptase may selectively block the formation of a viral DNA copy and thus possibly prevent the spread of retroviruses to new target cells. Only a few compounds have been shown effective in vivo, and a limited number of retrovirus inhibitors are under evaluation in clinical study programs as possible treatments for patients infected by the human immunodeficiency virus (HIV; 6, 9).
3'-Azido-3'-deoxythymidine (AZT; BW A509U) is an effective inhibitor of HIV multiplication in vitro (8) . This thymidine analog is phosphorylated to a monphosphate derivative by the cellular thymidine kinase (5) . The product is further phosphorylated by other cellular kinases to AZTtriphosphate (AZT-TP), which is a competitive inhibitor of HIV reverse transcriptase with respect to dTTP (5, 8; L. Vrang, H. Bazin, G. Remaud, J. Chattopadhyaya, and B. Oberg, Antiviral Res., in press). We studied the inhibitory mechanisms of AZT-TP and its threo isomer on avian myeloblastosis virus (AMV) reverse transcriptase activity. was synthesized at Astra ALAB AB, Sodertalje, Sweden.
MATERIALS AND METHODS
Reverse transcriptase assay. Unless otherwise indicated in the figure legends, the standard reaction was performed in 100-,ul mixtures containing 100 mM Tris hydrochloride (pH 8.0), 50 mM KCl, 10 mM MgCl2, 5 mM dithiothreitol, 400 ,ug of bovine serum albumin fraction V per ml, 0.05 A260 U (3.1 ,ug) of (rA)n-(dT)12_18 per ml, 10.6 ,uM data for foscarnet presented in the same manner resulted in a linear pattern almost identical to that observed for erythro-AZT-TP (data not shown).
DISCUSSION
The search for new and, it is hoped, more effective inhibitors of reverse transcriptases should benefit from a better understanding of the structural requirements for inhibitors. Modifications of nucleoside analogs at the 3' position have resulted in inhibitors such as AZT (8) and dideoxynucleosides (7) . These compounds are expected to undergo a series of phosphorylation steps to their corresponding triphosphates before being active as inhibitors of reverse transcriptases. We analyzed the inhibitory properties of threo-and erythro-AZT-TP on the AMV reverse transcriptase activity. The 3'-OH group in these compounds is replaced by a 3'-azido group directed upwards in the threo isomer and downwards in the erythro isomer.
We found that erythro-AZT-TP was a better inhibitor of AMV reverse transcriptase activity than was threo-AZT-TP when the natural substrate dTTP was varied in the reaction directed by (rA)n (dT)12_18. This is in accordance with previous observations for HIV reverse the AMV reverse transcriptase was less susceptible to inhibition by erythro-AZT-TP than was the HIV reverse transcriptase. A similar inhibition preference also held true for foscarnet (data not shown).
erythro-AZT-TP was found to be a competitive inhibitor of AMV reverse transcriptase when dTTP was the varied substrate. This corroborates previous observations for HIV reverse (4, 14) .
Since both isomers are dNTPs modified in the 3' position of the sugar moiety, it is expected that both compounds may serve as alternative substrates and on incorporation cause a termination of the growing DNA chain. The rapid termination of polymerase activity by erythro-AZT-TP added at different times of incubation ( Fig. 1 ) is in agreement with a distributive synthesis and an inhibition of chain elongation. The kinetic data obtained in our experiments support the alternative-substrate model for erythro-AZT-TP but not for threo-AZT-TP. Further incorporation studies need to be performed to elucidate the mechanisms involved. Inhibition by noncomplementary dNTPs was recently reported for DNA polymerase -y, purified from mouse myeloma MOPC 104E, in which dGTP and dATP were observed to compete with dTTP in an (rA)n * (dT)12_18-directed reaction (10) . When the same template primer was used, all three noncomplementary dNTPs (dATP, dCTP, and dGTP) were also reported to inhibit the activity of Rauscher murine leukemia virus reverse transcriptase in a noncompetitive manner, with apparent Ki values of 300 to 700 FM, indicating the existence of a second substrate-binding site (10) . We were, however, unable to detect any inhibition caused by dATP, dCTP, or dGTP at concentrations up to 1 mM in reactions using (rA)n. (dT)12_18 and the AMV reverse transcriptase.
Interactions between different inhibitors and reverse transcriptases, as well as other potential target enzymes, need to be further analyzed to improve our understanding of the structural requirements and to facilitate the design of more effective inhibitors, especially against the multiplication of HIV.
